StoxGlobal Health vs Piramal Pharma: share price & financials comparison
NSE: MEDANTA vs PPLPHARMA · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Global Health vs Piramal Pharma at a glance
Global Health (MEDANTA) has a market capitalisation of ₹39,065 Cr, against ₹32,484 Cr for Piramal Pharma (PPLPHARMA). Over the past year Piramal Pharma has returned +22.0%, compared with +16.4% for Global Health. Global Health earns a higher return on equity (9.2% vs -2.6%). Global Health comes out ahead on size, profitability, growth and financial health. Piramal Pharma comes out ahead on valuation, momentum and technicals. Across the scored metrics below, Global Health leads on 7 and Piramal Pharma on 7. On StoxGud's 10-point checklist, Global Health scores 6/10 and Piramal Pharma scores 6/10.
| Metric | Global Health | Piramal Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹39,065 Cr | ₹32,484 Cr |
| Revenue (latest FY) | ₹4,410 Cr | ₹8,869 Cr |
| Net profit (latest FY) | ₹556 Cr | ₹-326 Cr |
| Valuation | ||
| P/E | 98.2 | — |
| P/B | 9.04 | 3.99 |
| Dividend yield | 0.03% | 0.06% |
| Profitability | ||
| Return on equity | 9.2% | -2.6% |
| Net profit margin | 7.9% | -2.1% |
| Operating margin | 22.1% | 12.3% |
| Growth | ||
| Revenue growth (YoY) | +33.6% | +28.1% |
| Net profit growth (YoY) | -100.0% | — |
| Revenue CAGR (multi-year) | +17.9% | +7.8% |
| Financial health | ||
| Debt to equity | 0.16 | 0.70 |
| Momentum | ||
| 1-month return | +13.6% | +24.8% |
| 1-year return | +16.4% | +22.0% |
| 3-year CAGR | +16.9% | +26.7% |
| Distance from 52W high | -3.6% | -0.7% |
| Technicals | ||
| RSI (14) | 88 | 86 |
| Price vs 200-day avg | +15.9% | +35.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Global Health | Piramal Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Global Health or Piramal Pharma?
Global Health has a market cap of ₹39,065 Cr and Piramal Pharma has a market cap of ₹32,484 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Global Health or Piramal Pharma?
Piramal Pharma did better: Global Health returned +16.4% and Piramal Pharma returned +22.0% over one year.
What is the difference between Global Health and Piramal Pharma?
Both are NSE-listed companies in Healthcare. Global Health is about 1.2 times the size of Piramal Pharma by market cap. In the latest financial year Global Health reported revenue of ₹4,410 Cr and Piramal Pharma ₹8,869 Cr. Operating margin is 22.1% for Global Health and 12.3% for Piramal Pharma. Debt to equity is 0.16 for Global Health and 0.70 for Piramal Pharma.
Which is better, Global Health or Piramal Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Global Health leads on 7 and Piramal Pharma on 7. Global Health is ahead on size, profitability, growth and financial health. Piramal Pharma is ahead on valuation, momentum and technicals. On StoxGud's rules-based checklist Global Health scores 6/10 and Piramal Pharma scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.